Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 9/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5305202 | 0.79 | MAPK14 (0.37) | TOP2ATOP2BSIGMAR1 | |
| SCHEMBL6023252 | 0.76 | SIGMAR1 (0.35) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7734290 | 0.66 | TOP2A (0.97) | TOP2ATOP2BALDH1A1CYP1A2HPGD | |
| SCHEMBL549192 | 0.61 | TOP2A (1.00) | TOP2ATOP2B | |
| SCHEMBL7267539 | 0.60 | — | — | |
| Hydrochloric Acid SCHEMBL7732931 | 0.59 | TOP2A (0.97) | TOP2ATOP2B | |
| SCHEMBL18298165 | 0.59 | CYP1A2 (0.42) | TOP2ATOP2BCYP1A2 | |
| Hydrochloric Acid SCHEMBL7734294 | 0.57 | TOP2A (0.56) | TOP2ATOP2BALDH1A1CYP1A2HPGD | |
| SCHEMBL25138197 | 0.56 | KMT2A (0.55) | ALDH1A1NPSR1MAPKAPK2 | |
| SCHEMBL15244925 | 0.56 | MAPKAPK2 (0.59) | MAPKAPK2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| EP-0792271-B1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | UNIV GEORGIA STATE RES FOUND (US) | 2002-02-27 | — | — | EP | claimed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8110583-B2 | treatment of tumors; 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane; maintain cells in the G2/M cell cycle | MERCK PATENT GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| EP-2033959-B1 | Tetrahydropyranoquinoline derivatives | MERCK PATENT GMBH (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-7915416-B2 | Tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| WO-2005108355-A2 | DIHYDROBENZOTHIOPHENES | MERCK PATENT GMBH (DE) | 2005-11-17 | — | — | WO | disclosed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | disclosed |
| WO-2005063735-A1 | 2-(HETERO)-ARYL-SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-0792271-B1 | FURAN DERIVATIVES FOR INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA, GIARDIA LAMBLIA AND CRYPTOSPORIDIUM PARVUM | UNIV GEORGIA STATE RES FOUND (US) | 2002-02-27 | — | — | EP | disclosed |
| US-5602172-A | USING A 2,5-DIPHENYLFURAN COMPOUND | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | TOP2A 59/4885TOP2B 104/4885ALDH1A1 571/4885 |
| US-20050137185-A1 | Combinations of drugs for the treatment of neoplasms | MKI67, DHFR, IL5 | TOP2A 112/4885TOP2B 173/4885ALDH1A1 412/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | TOP2A 63/4885TOP2B 43/4885ALDH1A1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.